[go: up one dir, main page]

AU2001264747A1 - Identification of unique binding interactions between certain antibodies and thehuman b7.1 and b7.2 co-stimulatory antigens - Google Patents

Identification of unique binding interactions between certain antibodies and thehuman b7.1 and b7.2 co-stimulatory antigens

Info

Publication number
AU2001264747A1
AU2001264747A1 AU2001264747A AU6474701A AU2001264747A1 AU 2001264747 A1 AU2001264747 A1 AU 2001264747A1 AU 2001264747 A AU2001264747 A AU 2001264747A AU 6474701 A AU6474701 A AU 6474701A AU 2001264747 A1 AU2001264747 A1 AU 2001264747A1
Authority
AU
Australia
Prior art keywords
thehuman
identification
binding interactions
certain antibodies
unique binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001264747A
Inventor
Darrell R. Anderson
Peter Brams
Nabil Hanna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Idec Pharmaceuticals Corp
Original Assignee
Idec Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/576,424 external-priority patent/US7175847B1/en
Application filed by Idec Pharmaceuticals Corp filed Critical Idec Pharmaceuticals Corp
Publication of AU2001264747A1 publication Critical patent/AU2001264747A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001264747A 2000-05-22 2001-05-22 Identification of unique binding interactions between certain antibodies and thehuman b7.1 and b7.2 co-stimulatory antigens Abandoned AU2001264747A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/576,424 US7175847B1 (en) 1995-06-07 2000-05-22 Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
US09576424 2000-05-22
PCT/US2001/016364 WO2001089567A1 (en) 2000-05-22 2001-05-22 Identification of unique binding interactions between certain antibodies and the human b7.1 and b7.2 co-stimulatory antigens

Publications (1)

Publication Number Publication Date
AU2001264747A1 true AU2001264747A1 (en) 2001-12-03

Family

ID=24304362

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001264747A Abandoned AU2001264747A1 (en) 2000-05-22 2001-05-22 Identification of unique binding interactions between certain antibodies and thehuman b7.1 and b7.2 co-stimulatory antigens

Country Status (2)

Country Link
AU (1) AU2001264747A1 (en)
WO (1) WO2001089567A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020159996A1 (en) * 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
AU2002243718B2 (en) * 2001-01-31 2007-12-06 Biogen Idec Inc. Use of immunoregulatory antibodies in the treatment of neoplastic disorders
PT1565489E (en) * 2002-06-19 2011-02-23 Raven Biotechnologies Inc SPECIFIC INTERNALIZING ANTIBODIES FOR THE RAAG10 CELL SURFACE TARGET
US20060034845A1 (en) 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
EP1558645B1 (en) * 2002-11-08 2011-07-27 Ablynx N.V. Stabilized single domain antibodies in pharmaceutical composition adapted for inhalation
EP2301967A3 (en) 2002-11-08 2011-07-13 Ablynx N.V. Single domain antibodies for nasal administration
EP1599502A1 (en) * 2003-02-27 2005-11-30 TheraVision GmbH A molecule which binds cd80 and cd86
CA2667802A1 (en) * 2006-11-03 2008-05-29 Northwestern University Multiple sclerosis therapy
JP5601836B2 (en) 2006-11-08 2014-10-08 マクロジェニックス ウエスト， インコーポレイテッド TES7 and antibodies that bind to TES7
BRPI0809386A2 (en) * 2007-03-28 2014-09-09 Biogen Idec Inc TUMOR MICRO ENVIRONMENT MODULATION
WO2010042433A1 (en) 2008-10-06 2010-04-15 Bristol-Myers Squibb Company Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases
US8840889B2 (en) 2009-08-13 2014-09-23 The Johns Hopkins University Methods of modulating immune function
AU2019288635A1 (en) 2018-06-22 2021-01-21 Junten Bio Co., Ltd. Antibody inducing immune tolerance, induced lymphocyte, and cell therapy agent therapeutic method using induced lymphocyte

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4048294B2 (en) * 1996-11-08 2008-02-20 バイオジェン・アイデック・インコーポレイテッド Identification of unique binding interactions between certain antibodies and human B7.1 and B7.2 costimulatory antigens

Also Published As

Publication number Publication date
WO2001089567A1 (en) 2001-11-29

Similar Documents

Publication Publication Date Title
AU2508499A (en) Ligands of the cd47 antigen, agents binding the ligands of the cd47 antigen and uses thereof
IL223047A (en) Antibody comprising an fc region and uses thereof
AU2002251913A1 (en) Hybrid antibodies and uses thereof
AU3760100A (en) Immunostimulatory nucleic acids and antigens
AU2001264747A1 (en) Identification of unique binding interactions between certain antibodies and thehuman b7.1 and b7.2 co-stimulatory antigens
AU2002220843A1 (en) Humanised antibodies and uses thereof
ZA9810130B (en) Tumor-specific antigens methods for their production and their use for imunization and diagnosis
AU2001256325A1 (en) Human and humanized fap-alpha-specific antibodies
AU3159499A (en) Antigen preparation and use
AU2001248172A1 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
AU2001248176A1 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
AU2994599A (en) Active immunization against angiogenesis-associated antigens
AU2002217212A1 (en) Method for preparing a human monoclonal antibody, fragments thereof or antibodies comprising such fragments, resulting antibodies and use thereof
AU2001248171A1 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
ZA200107602B (en) Tuberculosis antigens and methods of use therefor.
AU757752C (en) Benzylidene pyrazolones, production and use thereof
AU2138601A (en) Chlamydia antigens and corresponding DNA fragments and uses thereof
AU2001261534A1 (en) The meca-79 antigen and related methods
AU4021800A (en) Human sperm surface antigens
AU2001245552A1 (en) Transcutaneous immunization for large particulate antigens
AU2002221428A1 (en) Novel polypeptide human polyadenylation binding protein 20.13 and polynucleotideencoding it
AU6227800A (en) Recombinant antibody directed against human sperm antigen
AU7788600A (en) Colon-tumour-associated antigens
AU4892199A (en) Serological diagnosis of protostrongylidae infections and identification of unique antigens
ZA981955B (en) Procedure for simultaneous determination of HIV antigens and HIV antibodies.